2,575 Shares of Moderna, Inc. $MRNA Acquired by Brighton Jones LLC

Brighton Jones LLC purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, HoldingsChannel.com reports. The firm purchased 2,575 shares of the company’s stock, valued at approximately $496,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of MRNA. Candriam S.C.A. lifted its stake in Moderna by 24.5% in the 3rd quarter. Candriam S.C.A. now owns 384,828 shares of the company’s stock worth $74,377,000 after purchasing an additional 75,632 shares in the last quarter. Ethic Inc. increased its holdings in shares of Moderna by 23.6% in the third quarter. Ethic Inc. now owns 19,394 shares of the company’s stock worth $3,735,000 after purchasing an additional 3,700 shares during the period. Parallel Advisors LLC raised its position in shares of Moderna by 8.8% in the third quarter. Parallel Advisors LLC now owns 5,082 shares of the company’s stock worth $979,000 after buying an additional 410 shares in the last quarter. Abacus Wealth Partners LLC purchased a new stake in shares of Moderna in the third quarter worth $259,000. Finally, Plancorp LLC bought a new stake in Moderna during the third quarter valued at $210,000. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MRNA shares. Bradesco Corretora upgraded Moderna to an “outperform” rating in a research report on Friday, August 28th. Bank of America raised their price target on Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, October 9th. JPMorgan Chase & Co. lifted their price target on Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Moderna in a report on Wednesday, September 9th. Finally, Citigroup reissued a “sell” rating on shares of Moderna in a report on Friday, October 23rd. Six research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $113.75.

Moderna News Summary

These are some of the MRNA news items that stood out recently:

• Positive Sentiment: Moderna lifted its 2026 revenue-growth forecast to 15%–25%, from a previous outlook of up to 10%, citing commercial progress including stronger overseas COVID-19 sales. Article
• Positive Sentiment: The company highlighted progress in its oncology pipeline, including its personalized cancer vaccine, positioning cancer treatments as a potential longer-term growth driver. Article
• Negative Sentiment: Investors are concerned about roughly $4 billion in planned 2027 cash costs, much of it tied to pipeline investment, while visibility into future revenue growth remains limited. Coverage also noted that the 2026 revenue outlook may fall short of analyst expectations, tempering the more optimistic growth forecast. Article

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 40,294 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the sale, the president owned 1,525,858 shares in the company, valued at $219,921,913.54. The trade was a 2.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by corporate insiders.

Moderna Stock Down 3.4%

Shares of NASDAQ:MRNA opened at $223.37 on Friday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $280.80. The firm has a fifty day moving average of $201.67 and a 200 day moving average of $96.41. The firm has a market capitalization of $90.38 billion, a PE ratio of -31.46 and a beta of 1.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 25.79% and a negative net margin of 110.46%. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $890.25 million. During the same quarter last year, the business posted ($0.51) earnings per share. The company’s revenue for the quarter was up 29.2% on a year-over-year basis. As a group, research analysts anticipate that Moderna, Inc. will post -5.34 EPS for the current fiscal year.

About Moderna

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.